Skip to content

Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study

Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05071352
Enrollment
60
Registered
2021-10-08
Start date
2021-10-01
Completion date
2023-03-31
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Critical Illness, Mechanical Ventilation, Sedation

Keywords

Nefopam, Ketamine, Standard of care, Sedation, Critically ill, Mechanical ventilation, Propofol, Fentanyl, Midazolam, Delirium, Vasopressors.

Brief summary

The aim of this prospective, randomized, active control, double blinded study is to assess the effect and safety of continuous infusion nefopam in mechanically ventilated ICU patients compared to standard of care. It is being hypothesized that continuous infusion nefopam will reduce opioid use with acceptable safety profile compared to standard of care.

Detailed description

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. Critically ill patients experience pain at rest and during standard caring procedures. Arterial catheter insertion, chest tube removal, wound drain removal, wound care, and turning are associated with the greatest increased pain intensity. Pain have short and long-term sequelae on critically ill patients. Short-term sequelae include impaired tissue oxygenation, impaired wound healing, and impaired immune functions. Long-term sequelae include chronic pain, Post-traumatic stress disorder (PTSD) symptoms, and a lower health-related quality of life. The gold standard for pain assessment is patient's self-report of pain. For critically ill able to self-report pain the 0-10 numeric rating scale in a visual format (NRS-V) is the best to use. Unfortunately, a lot of critically ill patients are unable to communicate and self-report pain. So, using behavioral pain scales are suitable in this type of patients, Critical care pain observation tool (CPOT) demonstrates validity and reliability for monitoring pain in critical ill adult patient who are unable to self-report pain and in whom behaviors are observable. The 2018 Pain, Agitation/sedation, Delirium, Immobility, and Sleep disruption (PADIS) guideline panel suggests using an assessment-driven, protocol-based, stepwise approach for pain and sedation management in critically ill adults and state as a good practice statement critically ill adults should be regularly assessed for delirium using a valid tool. Opioids are a cornerstone in the management of pain in critically ill patient, but have a lot of negative consequences including constipation, urinary retention, bronchospasm, over-sedation, respiratory depression, hypotension, nausea, truncal rigidity, delirium, and immunosuppression. Also, they contribute to vasodilatation and hypotension which lead to increased resuscitation fluids volume in critically ill patient. Multi-modal analgesia also known as balanced analgesia approach via using non-opioids adjuvant or in replacement of opioids to target different pain pathways leads to optimizing analgesia and reducing opioids consumption. In France, the second most prescribed non-opioids in mechanically ventilated intensive care unit (ICU) patient is nefopam. Nefopam is a non-opioid, non-steroidal centrally acting analgesic, although the exact mechanism of action poorly understood, analgesic activity is thought to be via inhibiting dopamine, norepinephrine, serotonin reuptake. Nefopam was non-inferior to fentanyl for pain control in patients undergoing elective cardiac surgery without increase in adverse effects. Nefopam has a fentanyl sparing effect up to 50% in patients underwent laparoscopic total hysterectomy. The 2018 PADIS guideline panel made a conditional recommendation for using nefopam (if feasible) either as an adjunct or replacement for an opioid to reduce opioid use and their safety concerns for pain management in critically ill adults. Therefore, the aim of this prospective, randomized, active control, double blinded study is to assess the effect and safety of continuous infusion nefopam in mechanically ventilated ICU patients compared to standard of care. It is being hypothesized that continuous infusion nefopam will reduce opioid use with acceptable safety profile compared to standard of care.

Interventions

DRUGNefopam

Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.

DRUGStandard of care in the ICU for assessment and management of pain, sedation, and delirium.

In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult patients \>18 years on mechanical ventilation and expected to need ventilatory support for the next 24 hours. 2. Candidate for sedation and analgesia protocol

Exclusion criteria

1. Pregnant and/or lactating woman. 2. Has been intubated for duration longer than 12 hours in an intensive care unit. 3. Proven or suspected acute primary brain lesion such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury. 4. Proven or suspected spinal cord injury or other pathology that may result in permanent or prolonged weakness. 5. Admission as a consequence of a suspected or proven drug overdose 6. Mean arterial pressure (MAP) \< 50 mmHg despite adequate resuscitation and vasopressor therapy at time of randomization. 7. Death is deemed to be imminent or inevitable during this admission and either the attending physician, patient or substitute decision maker is not committed to active treatment. 8. Patients with severe hepatic impairment (Child-Pugh class C) or end stage renal disease (ESRD) (creatinine clearance \< 30 ml/min or on chronic hemodialysis) due to altered pharmacokinetics \[20\]. 9. Need for deep sedation such as administration of neuromuscular blockers. 10. Convulsions or previous history of convulsions. 11. Risk of urinary retention linked to uretroprostatic disorders. 12. Risk of acute angle glaucoma. 13. Known intolerance of or hypersensitivity to study medications or constituents.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative dose of fentanylFirst 24 hour after randomization.To compare the cumulative dose of fentanyl

Secondary

MeasureTime frameDescription
pain scoreFirst 24 hours after randomization.To compare number of patients are in Pain score goal. If patient able to communicate we use the 0-10 numeric rating scale in a visual format (NRS-V), 0 indicate no pain and 10 indicate the worst pain imaginable. For patient unable to communicate we use Critical care pain observation tool (CPOT) score, a score ≥3 indicate significant pain.
Duration of mechanical ventilation (MV)The number of calendar days from intubation date to extubation date, until ICU discharge, death, or 28 days post-randomization, whichever comes first.To assess whether nefopam can help to shorten the of being mechanically ventilated.
Use of physical restraint24 hour after randomizationUse of physical restraint
vasopressor requirementsFirst 24 hours after randomization.To compare vasopressors requirement
HemodynamicsFirst 24 hours after randomization.changes in Mean Arterial Pressure (MAP) mmHg
ICU length of stay (LOS)From randomization to ICU discharge dateTo compare ICU LOS
Richmond Agitation and Sedation Score (RASS)First 24 hours after randomization.To compare number of patients are in RASS score goal. RASS score minumum -5 (unarousable), maximun +4 (Combative). Goal RASS score from -1 (drowsy) to 0 (alert and calm).
Unplanned extubation (self-extubation)28 days post-randomizationUnplanned extubation date rate
Re-intubation28 days post-randomizationRe-intubation rate
Incidence of delirium24 hour after randomizationRate of positive confusion assessment method for the ICU (CAM-ICU) score
Use of antipsychotics24 hour after randomizationRate of using antipsychotics for confirmed ICU-acquired delirium
Mortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.28 days after randomizationMortality rate at the time of hospital discharge or 28 days after randomization, whichever comes first.
Tracheostomy28 days post-randomizationTracheostomy rate

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026